• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by GH Research PLC

    2/27/25 8:34:59 AM ET
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHRS alert in real time by email
    S-8 1 ny20044079x2_s8.htm S-8

    As filed with the Securities and Exchange Commission on February 27, 2025
    Registration No. 333-


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549



    FORM S-8
    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933
     

     
    GH Research PLC
    (Exact Name of Registrant as specified in its charter)

    Ireland
    N/A
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification No.)

     
    GH Research PLC
    Joshua Dawson House
    Dawson Street
    Dublin 2
    D02 RY95
    Ireland
    Tel: +353 1 437 8334
     
    (Address, including zip code, and telephone number, including area code, of Principal Executive Offices)



    GH Research PLC Share Option Plan
     
    (Full title of the plan)
     



    Cogency Global Inc.
    122 East 42nd Street, 18th Floor
    New York, NY 10168
    Tel: (800) 221-0102
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     
    Copies to:
     
     
    Adam Kaminsky
    Davis Polk & Wardwell LLP
    450 Lexington Avenue
    New York, NY 10017
    (212) 450-4000
     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
    Accelerated filer ☒
    Non-accelerated filer ☐ (Do not check if a smaller reporting company)
    Smaller reporting company ☐
     
    Emerging Growth Company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    PART I

    REGISTRATION OF ADDITIONAL SECURITIES PURSUANT TO GENERAL INSTRUCTION

    Pursuant to General Instruction E to Form S-8, GH Research PLC (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) with the U.S. Securities and Exchange Commission (the “Commission”) to register 999,970 additional ordinary shares, nominal value $0.025 per share, for issuance under the GH Research PLC Share Option Plan, as amended November 24, 2024. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on March 9, 2023 (Registration No. 333-270422).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.  Incorporation of Documents by Reference.

    The following documents are incorporated herein by reference:

    (a) The annual report on Form 20-F of GH Research PLC (the “Registrant”) for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025; and

    (b) The description of the Registrant’s share capital which is contained in the Registrant’s Registration Statement on Form 8-A (Registration No. 001-40530), dated June 22, 2021, including any amendments or supplements thereto.

    In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, including any Reports of Foreign Private Issuers on Form 6-K submitted during such period (or portion thereof) that is identified in such form as being incorporated by reference into this Registration Statement, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. The Registrant is not incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 8.  Exhibits.

    Exhibit
    Number
       
    4
     
    Constitution of GH Research PLC (incorporated herein by reference to Exhibit 1.1 of the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022, filed with the Commission on March 9, 2023).

    5
     
    Opinion of A&L Goodbody LLP (filed herewith)

    23.1
     
    Consent of A&L Goodbody LLP (included in Exhibit 5)

    23.2
     
    Consent of PricewaterhouseCoopers an independent registered public accounting firm (filed herewith)

    24
     
    Powers of Attorney (included in the signature pages hereto)

    99
     
    GH Research PLC Share Option Plan, as amended November 24, 2024 (incorporated by reference to Exhibit 4.1 of the Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025)

    107
     
    Filing Fee Table


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on this 27th day of February, 2025.

     
    GH Research PLC

     
    By:
    /s/ Julie Ryan
     
    Name:
    Julie Ryan
     
    Title:
    Vice President, Finance
         



    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Velichka Valcheva and Julie Ryan, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and any and all additional registration statements pursuant to Rule 462(b) of the Securities Act and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature
     
    Title
    Date
     
    /s/ Velichka Valcheva 
     
    Chief Executive Officer
    February 27, 2025
    Velichka Valcheva
     
    (Principal Executive Officer)
     
     
    /s/ Julie Ryan 
     
    Vice President, Finance
    February 27, 2025
    Julie Ryan
     
    (Principal Financial Officer and Principal Accounting Officer)
     
     
    /s/ Florian Schönharting 
     
    Director
    February 27, 2025
    Florian Schönharting
         
     
    /s/ Michael Forer 
     
    Director
    February 27, 2025
    Michael Forer
         
     
    /s/ Dermot Hanley 
     
    Director
    February 27, 2025
    Dermot Hanley
         
     
    /s/ Duncan Moore 
     
    Director
    February 27, 2025
    Duncan Moore
         



    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in New York, NY on February 27, 2025.


    Authorized U.S. Representative--Cogency Global Inc.
         
     
    By:  
    /s/ Colleen A. De Vries
       
    Name: Colleen A. De Vries
     
    Title: Senior Vice-President on behalf of
     
    Cogency Global Inc.



    Get the next $GHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHRS

    DatePrice TargetRatingAnalyst
    6/4/2025$25.00Overweight
    Cantor Fitzgerald
    3/13/2025$32.00Buy
    Guggenheim
    3/7/2025$31.00Outperform
    RBC Capital Mkts
    2/13/2025$14.00Overweight
    Cantor Fitzgerald
    8/16/2022$45.00Buy
    H.C. Wainwright
    6/16/2022$66.00Buy
    ROTH Capital
    7/20/2021Buy
    Stifel
    7/20/2021$35.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (

      5/15/25 7:00:00 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

      Primary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $315.3 million as of March 31, 2025 DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2025, and provided updates on its business. Business Updates GH001 in Patients with TRD Our multi-center, randomize

      5/8/25 7:00:03 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

      Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy volunteers is ongoing in the UKFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial assets and marketable securities of $182.6 million as of December 31, 2024Net cash proceeds of an additional $139.8 million from public offering received in February 2025 DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming t

      2/27/25 7:00:25 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    SEC Filings

    See more
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/27/25 7:00:30 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GH Research PLC

      6-K - GH Research PLC (0001855129) (Filer)

      5/21/25 7:00:41 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by GH Research PLC

      SCHEDULE 13G/A - GH Research PLC (0001855129) (Subject)

      5/15/25 4:58:22 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 5:46:11 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GH Research PLC

      SC 13G/A - GH Research PLC (0001855129) (Subject)

      11/14/24 9:05:43 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GH Research PLC

      SC 13G - GH Research PLC (0001855129) (Subject)

      2/16/24 4:57:41 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

      DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced the promotion of Dr. Velichka "Villy" Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company's Chief Medical Officer since February 2024 having leadership responsibility, among other thin

      9/3/24 7:00:05 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

      DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $238.1 million as of June 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise inv

      8/23/23 7:00:45 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Financials

    Live finance-specific insights

    See more
    • GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

      Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group (p<0.0001)All other secondary endpoints were met with clinically and statistically significant improvements on Day 8, compared with placeboDuring the double-blind part, GH001 was well tolerated and no serious adverse events (SAE) were reported. There was no evidence of treatment-emergent suicidal ideation or behavior. As of January 22, 2025, no SAEs have been reported throughout the open

      2/3/25 7:00:10 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

      DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under "Events & Presentations" in the Investors section of GH Research PLC's website at ghres.com. About GH Research PLC GH

      1/31/25 4:01:35 PM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on GH Research PLC with a new price target

      Cantor Fitzgerald resumed coverage of GH Research PLC with a rating of Overweight and set a new price target of $25.00

      6/4/25 8:19:53 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on GH Research PLC with a new price target

      Guggenheim initiated coverage of GH Research PLC with a rating of Buy and set a new price target of $32.00

      3/13/25 7:38:21 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on GH Research PLC with a new price target

      RBC Capital Mkts initiated coverage of GH Research PLC with a rating of Outperform and set a new price target of $31.00

      3/7/25 7:25:01 AM ET
      $GHRS
      Biotechnology: Pharmaceutical Preparations
      Health Care